New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 19, 2012
13:23 EDTCELGCelgene's Lazorchak charged with insider trading, Bloomberg reports
John Lazorchak, the director of financial reporting at Celgene (CELG), and five others have been charged with insider trading by U.S. prosecutors in New Jersey, Bloomberg reports. Reference Link
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2014
07:39 EDTCELGCelgene reinstated with a Buy at BofA/Merrill
Target $112.
September 29, 2014
08:55 EDTCELGCelgene price target raised to $115 from $100 at RBC Capital
RBC Capital increased its price target on Celgene (CELG) as the firm now estimates that the company's new oral Crohn's disease drug GED-0301 will generate $1B in sales. The firm expects Celgene's stock to rise further as it predicts that Phase II data for the company's Crohn's treatment will be much better than the data for AbbVie's (ABBV) Crohn's treatment, Humira. RBC predicts that Celgene's long-term 2020 guidance will beat expectations if the company is able to reach a legal settlement with Actavis (ACT.). RBC Capital keeps an Outperform rating on Celgene.
07:26 EDTCELGInforma Business Information to hold a conference
Subscribe for More Information
September 25, 2014
09:36 EDTCELGActive equity options trading on open
Subscribe for More Information
September 24, 2014
13:17 EDTCELGCelgene continues rally after FDA approval of psoriasis drug
Subscribe for More Information
07:01 EDTCELGCelgene OTEZLA to become important revenue generator, says Cantor
Subscribe for More Information
September 23, 2014
15:21 EDTCELGCelgene announces FDA approves Otezla for treating plaque psoriasis
Subscribe for More Information
September 22, 2014
07:21 EDTCELGEBD Group to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use